Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bleb Vascularity Conjunctival Scarring

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

bleb vascular change bevacizumab trabeculectomy Bleb vascularity associated with increased scarring activity Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bevacizumab

0.05ml, 1.25mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Glaucoma patients after trabeculectomy whose bleb is hyperaemia

Exclusion Criteria

* Affected eye has normal IOP
* Not allergic with Avastin

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Beiing Tongren hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Liu Xuan, M.D.

Role: PRINCIPAL_INVESTIGATOR

An ophthalmologist in Tongren hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tongren hospital

Beijing, Beijing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008TR-LX-001

Identifier Type: -

Identifier Source: org_study_id